The Latest in the Hepatitis B Drug Pipeline
Why cost and treatment length are some of the biggest concerns for drug manufacturers.
Peptic Ulcer Disease Drug Pipeline: What You Need to Know
The current and future treatments for the $10 billion condition.
Eight Top Oncology Drug Approvals
New cancer drugs continue to offer patients hope. Here are eight of them.
Oncology Pipeline Predictions
This year has been another year full of oncology approvals, proving that the oncology pipeline is robust with first-of-the kind molecules, competitor products for existing agents, and biosimilars.
How Tweaking Therapies Can Help Mental Health Treatment
Not all therapies work the same in every patient, but that’s not the biggest challenge in treating mental health. This is.
Three Vaccine Developments Healthcare Execs Should Watch
Vaccines are an important part of creating “herd immunity” to keep infectious diseases in check. Here are three vaccine developments that have far reaching implications for public health.
Top Advancements in Lung Cancer: What Health Execs Should be Watching
Oncology experts shed light on progress of genetic testing and targeted therapies in lung cancer.
HIV Pipeline Prospects Getting Healthier
There is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Groundbreaking gene therapies in store for hemophilia
Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
Autoimmune drug pipeline highlights
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Oncology treatments: Three areas to watch
While targeted cancer therapies make up a big part of the pipeline, there are three areas that oncology experts want you to keep on your radar.
Pediatric drug market poised for growth
More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.
Oral specialty drug options on the horizon
As more specialty drugs are approved, cost control strategies are key.
Brace for a barrage of biosimilars
The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Evolving hepatitis C pipeline offers hope to patients
Cost burden prompts payers to consider appropriate utilization
Pharmaceutical pipeline: Top 4 conditions to watch
Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
New therapies show promise in treating diabetes
New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Cannabinoid-based drug pipeline shows promise
New treatment indications are under investigation for the use of cannabinoid-based drugs.
New diabetes medications help address linked diseases
Experts share updates on new diabetes medications, and provide an overview of what’s coming.
2 Commerce Drive Cranbury, NJ 08512